Long-term Study of Asenapine in Subjects With Residual Subtype, Receiving Multiple or/and High Dose Drugs, or Treatment Refractory Schizophrenia (Protocol P06238).
Phase of Trial: Phase III
Latest Information Update: 28 Aug 2015
At a glance
- Drugs Asenapine (Primary)
- Indications Schizophrenia
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme
- 10 Jun 2017 Biomarkers information updated
- 22 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 17 Oct 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.